These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 9338023

  • 1. Octreotide scanning for carcinoid tumours.
    Critchley M.
    Postgrad Med J; 1997 Jul; 73(861):399-402. PubMed ID: 9338023
    [Abstract] [Full Text] [Related]

  • 2. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J.
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
    [Abstract] [Full Text] [Related]

  • 3. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O, Kölby L, Wängberg B, Wigander A, Billig H, William-Olsson L, Fjälling M, Forssell-Aronsson E, Ahlman H.
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [Abstract] [Full Text] [Related]

  • 4. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor.
    Rufini V, Salvatori M, Saletnich I, Valenza V, Maussier ML, Martino G, Corsello SM, Pantusa M, Casolo A, Troncone L.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
    Westlin JE, Janson ET, Arnberg H, Ahlström H, Oberg K, Nilsson S.
    Acta Oncol; 1993 Dec; 32(7-8):783-6. PubMed ID: 8305227
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
    Hillman N, Herranz L, Alvarez C, Martínez Olmos MA, Márco A, Gómez-Pan A.
    Exp Clin Endocrinol Diabetes; 1998 Dec; 106(3):226-30. PubMed ID: 9710364
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
    Janson ET, Westlin JE, Eriksson B, Ahlström H, Nilsson S, Oberg K.
    Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
    [Abstract] [Full Text] [Related]

  • 18. Octreotide LAR in carcinoid: how to dose?
    Yao JC, Kvols LK.
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours.
    Nocaudie-Calzada M, Huglo D, Carnaille B, Proye C, Marchandise X.
    Eur J Nucl Med; 1996 Nov; 23(11):1448-54. PubMed ID: 8854840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.